Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,675.00    -185.00 (-3.87%)
Bid:
4,600.00
Ask:
4,750.00
Spread: 150.00 (3.261%)
Market Cap: £306.39m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition and Trading Update

27 Jun 2013 07:00

RNS Number : 9611H
Judges Scientific PLC
27 June 2013
 



Judges Scientific plc

 

ACQUISITION OF SCIENTIFICA LIMITED

 

27 June 2013

 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges", the "Company" or the "Group")

ACQUISITION OF SCIENTIFICA LIMITED AND TRADING UPDATE

Judges Scientific, the parent company of a group engaged in the design, manufacture and sale of scientific instruments, announces that on 26 June 2013 it acquired 100% of the issued share capital of Scientifica Limited ("Scientifica"), specialist manufacturers of electrophysiology equipment, for a cash consideration of £12.0 million and an earn-out capped at £1.0 million (the "Acquisition").

An additional payment will be made to reflect any excess working capital over and above the ongoing requirements of the business. Judges expects such payment to be covered by the cash inherited as at the completion date.

Information on Scientifica

Scientifica designs, manufactures and sells complete instrument rigs used in electrophysiology, comprised of micromanipulators, optical microscopes and associated mounting solutions. The company also distributes a range of complementary products including imaging systems, multi-electrode arrays, amplifiers, perfusion equipment and light sources. The products are sold worldwide to academic institutions, research centres and pharmaceutical companies for the purpose of conducting electrophysiology research with a particular emphasis on neuroscience.

Scientifica was founded in 1996 by Mark Johnson and David Rogerson, who developed it as joint Managing Directors and who each owned a 50% interest in the company's share capital. During recent months, Matt Kemp joined the senior management team as Sales Director. Shortly before completion, Mr Kemp exercised options to acquire 5% of the enlarged equity, thereby reducing the respective holdings of Mr Johnson and Mr Rogerson to 47.5% each. Following the Acquisition, Mr Rogerson will not stay with the company, which will be run by Mr Johnson and Mr Kemp who will remain in their respective positions.

The company has concentrated its operations on the supply of systems, which are configured to meet the specific requirements of individual customers. This customer focus has enabled Scientifica to achieve a compound annual growth rate of 31% over the past five years. Exports represent two-thirds of total revenues and Scientifica's performance in overseas markets was recognised in 2012 when the company received a Queen's Award for Enterprise - International Trade.

Scientifica's unaudited accounts for the financial year to 31 March 2013 show revenues of £9.2 million and pre-tax profits of £2.2 million. Operating profit adjusted to eliminate non-recurring items and to reflect Judges' practices would have totalled £2.1 million. The accounts show net tangible assets of £3.65 million, including cash of £1.25 million.

The earn-out will amount to £1.0 million if Scientifica generates operating profits of £2.167 million or more in respect of the twelve month period to 31 March 2014, reducing by six times any shortfall below £2.167 million. Half of the earn-out will be paid in cash and half through the issue of new Ordinary shares ("Ordinary Shares") in Judges at a price of 1180p per Ordinary Share, based on the prevailing price of Judges' Ordinary Shares on the day the Acquisition was agreed in principle. For accounting purposes, fluctuations in the share price will have a commensurate impact on the book value of the earn-out cap.

The Acquisition is expected to be earnings enhancing with immediate effect. The Board believes that Scientifica is an excellent business operating in an expanding niche with considerable worldwide growth potential.

Financing of the Acquisition

As at 31 December 2012, the date of the last published balance sheet, the Group's adjusted net debt amounted to £1.7 million supported by borrowing facilities of £10.7 million. The Acquisition and associated transaction costs are being financed from existing cash resources and an additional £9.0 million term loan ("Loan") provided by Lloyds Bank Corporate Markets. The Loan is repayable over a five year period.

Judges' Trading Performance

The Group's trading performance since the beginning of the current financial year has remained satisfactory. Order intake was strong in the first quarter and more subdued since, resulting in 4.7% organic growth in order intake compared to the first 25 weeks of 2012. This is consistent with market expectations for the year as a whole.

Alex Hambro, Chairman of Judges, commented:

"The purchase of Scientifica represents the largest acquisition made by Judges Scientific and its impact on the Group's financial performance should be significant. We are delighted that Mark Johnson and Matt Kemp will continue to manage the company and we welcome them to Judges' expanding team."

 

For further information please contact:

Judges Scientific Plc

David Cicurel, CEO

Tel: 01342 323 600

 

Shore Capital (Nominated Adviser & Broker)

Edward Mansfield

Tel: 020 7408 4090

 

Cardew Group (Financial Public Relations)

Melvyn Marckus

Tel: 020 7930 0777 or 07775 896 491

 

Websites:

Judges Scientific: www.judges.uk.com 

Scientifica: http: www.scientifica.uk.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQFFMMTMBBTTJJ
Date   Source Headline
25th Apr 20235:55 pmRNSDirector/PDMR Shareholding
6th Apr 20232:50 pmRNSDirector/PDMR Shareholding
4th Apr 202312:21 pmRNSTotal Voting Rights
3rd Apr 20237:01 amRNSAcquisition of Henniker Scientific Limited
3rd Apr 20237:00 amRNSAppointment of Joint Broker
31st Mar 20238:54 amRNSGrant of Options
22nd Mar 20237:00 amRNSFinal Results
8th Mar 20232:39 pmRNSTotal Voting Rights
8th Mar 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20238:48 amRNSDirector/PDMR Shareholding
2nd Feb 20239:17 amRNSDirector/PDMR Shareholding
1st Feb 20237:00 amRNSExecutive Director and Board Appointment
1st Feb 20237:00 amRNSTotal Voting Rights
23rd Jan 202310:27 amRNSGrant of Options
19th Jan 20237:00 amRNSFull Year Trading Statement and Notice of Results
9th Jan 20237:00 amRNSDirector/PDMR Shareholding
3rd Jan 20231:03 pmRNSTotal Voting Rights
21st Dec 202210:51 amRNSBlock listing Interim Review
20th Dec 202211:53 amRNSDirector/PDMR Shareholding
12th Dec 20228:52 amRNSHolding(s) in Company
6th Dec 20222:34 pmRNSDirector/PDMR Shareholding
1st Dec 202210:01 amRNSTotal Voting Rights
30th Nov 20224:41 pmRNSSecond Price Monitoring Extn
30th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20228:54 amRNSDirector/PDMR Shareholding
7th Nov 20225:14 pmRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSDirector/PDMR Shareholding
4th Oct 20223:55 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:01 amRNSTotal Voting Rights
23rd Sep 20223:44 pmRNSDirector/PDMR Shareholding
22nd Sep 20227:00 amRNSInterim Results
6th Sep 20222:51 pmRNSDirector/PDMR Shareholding
2nd Sep 20223:16 pmRNSTotal Voting Rights
9th Aug 20229:20 amRNSDirector/PDMR Shareholding
1st Aug 202211:07 amRNSTotal Voting Rights
27th Jul 20224:08 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
8th Jul 20228:12 amRNSDirector/PDMR Shareholding
1st Jul 20225:34 pmRNSTotal Voting Rights
29th Jun 202211:13 amRNSDirector/PDMR Shareholding
27th Jun 20227:00 amRNSAcquisition of minority shareholding in Bordeaux
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
10th Jun 202211:43 amRNSBlocklisting Return
9th Jun 202212:11 pmRNSDirector/PDMR Shareholding
9th Jun 20227:36 amRNSIssue of Shares – Replacement
8th Jun 20223:52 pmRNSIssue of Ordinary Shares
6th Jun 20223:00 pmRNSPurchase of Ordinary Shares
1st Jun 202212:48 pmRNSTotal Voting Rights
27th May 20221:08 pmRNSAppointment of auditor
24th May 20222:12 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.